Language: English

Threads containing posts by Natuli

 

5	286	Free sucrose GC  pharm.	Natuli	3.03.2010	17:31
3	358	peak of ХХ shows a specific UV-spectrum  pharm.	Natuli	3.03.2010	15:52
6	192	DIN  pharm.	Natuli	3.03.2010	13:07
2	330	Frequency of Full Testing  pharm.	Natuli	3.03.2010	0:44
5	428	DATE OF REVISION OF THE TEXT  pharm.	Natuli	6.02.2010	14:11
2	266	as potassium  pharm.	Natuli	6.02.2010	14:04
3	291	co-administration with rifampicin is unavoidable  pharm.	Natuli	5.02.2010	23:51
5	1137	Nature and contents of container  pharm.	Natuli	5.02.2010	23:50
2	153	accounting for much of the AUC  pharm.	Natuli	4.02.2010	22:21
2	118	isoform-selective chemical inhibitors and cDNA-expressed  pharm.	Natuli	4.02.2010	22:20
3	329	Non-completer is failure imputation  pharm.	Natuli	4.02.2010	10:25
6	393	Non-Clade B  pharm.	Natuli	4.02.2010	10:11
8	327	to any appreciable extent.  pharm.	Natuli	4.02.2010	9:11
3	221	were carried forward for percent и baseline-carry-forward  pharm.	Natuli	4.02.2010	9:08
2	240	FVIII KO mice  pharm.	Natuli	22.01.2010	12:11
4	154	Subject 101004, 101006 and 101011 30 min ХХ are excluded  pharm.	Natuli	21.01.2010	19:14
4	181	Marketing Experience /Not applicable  pharm.	Natuli	21.01.2010	19:13
2	612	Conduit vein ангиопластика  med.	IuriiA	21.01.2010	13:47
2	149	mini-bags  pharm.	Natuli	21.01.2010	11:02
5	1654	The treatment ratio  pharm.	Natuli	21.01.2010	9:54
2	384	the rate of decline in FVIII:C activity/tendency to a biexponential decay pattern  pharm.	Natuli	21.01.2010	8:57
2	170	frequencies of adverse events have been summarised by treatment  pharm.	Natuli	20.01.2010	22:08
2	209	were to be collected ; were to be reported	Natuli	20.01.2010	21:30
2	224	unique patients/ first session,  pharm.	Natuli	20.01.2010	20:22
5	247	Product Strength и 95% CI - geom  pharm.	Natuli	18.01.2010	15:59
7	1453	incremental recovery values  pharm.	Natuli	18.01.2010	15:25
4	205	first human dose, pharmacokinetic, safety, single dose trial using a sequential design  pharm.	Natuli	18.01.2010	10:25
2	252	ongoing pivotal trial и completed FHD trial  pharm.	Natuli	18.01.2010	9:30
2	188	prior to submission for comments  pharm.	Natuli	15.01.2010	22:23
2	361	International Medical Director  med.	Natuli	15.01.2010	22:22

Pages 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21